Compare Stocks: GRTS, INTS, ELOX, and DARE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DARE Dare Bioscience	$0.81 -1.8%	$1.65	$0.75 ▼ $3.78	$12.60M	1.08	1.00 million shs	502,412 shs
ELOX Eloxx Pharmaceuticals	$18.04 -0.7%	$14.17	$8.20 ▼ $19.96	$12.50M	-1864.08	54,500 shs	40,274 shs
GRTS Gritstone bio	$0.03	$0.35	$0.03 ▼ $3.17	$3.50M	0.49	7.01 million shs	N/A
INTS Intensity Therapeutics	$4.88 +16.2%	$4.30	$3.51 ▼ $43.50	$13.71M	2.76	26,981 shs	63,612 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DARE Dare Bioscience	-1.84%	-40.93%	-35.26%	-65.86%	-60.72%
ELOX Eloxx Pharmaceuticals	-0.66%	-5.40%	+50.33%	-58.59%	+∞
GRTS Gritstone bio	0.00%	0.00%	0.00%	0.00%	0.00%
INTS Intensity Therapeutics	+16.19%	+22.00%	+10.91%	+3.61%	-34.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DARE Dare Bioscience	$0.81 -1.8%	$1.65	$0.75 ▼ $3.78	$12.60M	1.08	1.00 million shs	502,412 shs
ELOX Eloxx Pharmaceuticals	$18.04 -0.7%	$14.17	$8.20 ▼ $19.96	$12.50M	-1864.08	54,500 shs	40,274 shs
GRTS Gritstone bio	$0.03	$0.35	$0.03 ▼ $3.17	$3.50M	0.49	7.01 million shs	N/A
INTS Intensity Therapeutics	$4.88 +16.2%	$4.30	$3.51 ▼ $43.50	$13.71M	2.76	26,981 shs	63,612 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DARE Dare Bioscience	-1.84%	-40.93%	-35.26%	-65.86%	-60.72%
ELOX Eloxx Pharmaceuticals	-0.66%	-5.40%	+50.33%	-58.59%	+∞
GRTS Gritstone bio	0.00%	0.00%	0.00%	0.00%	0.00%
INTS Intensity Therapeutics	+16.19%	+22.00%	+10.91%	+3.61%	-34.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DARE Dare Bioscience	2.50	Moderate Buy	$10.00	1,135.79% Upside
ELOX Eloxx Pharmaceuticals	2.33	Hold	$41.50	130.04% Upside
GRTS Gritstone bio	0.00	N/A	N/A	N/A
INTS Intensity Therapeutics	2.80	Moderate Buy	$7.00	43.44% Upside

Current Analyst Ratings Breakdown

Latest GRTS, INTS, ELOX, and DARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	INTS Intensity Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $7.00
8/17/2026	DARE Dare Bioscience	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	ELOX Eloxx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/11/2026	INTS Intensity Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/22/2026	ELOX Eloxx Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$40.00
7/21/2026	INTS Intensity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/20/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$43.00
7/20/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$43.00
7/17/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DARE Dare Bioscience	$1.03M	12.01	N/A	N/A	($0.04) per share	-20.23
ELOX Eloxx Pharmaceuticals	$6.36M	1.96	N/A	N/A	$67.43 per share	0.27
GRTS Gritstone bio	$496K	7.05	N/A	N/A	$0.54 per share	0.06
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	$2.82 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DARE Dare Bioscience	-$13.40M	-$0.70	N/A	N/A	N/A	-803.80%	-748.30%	-38.75%	N/A
ELOX Eloxx Pharmaceuticals	-$5.99M	-$1.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GRTS Gritstone bio	-$138.49M	-$1.24	N/A	N/A	N/A	-910.50%	-328.51%	-82.53%	N/A
INTS Intensity Therapeutics	-$11.61M	-$3.57	N/A	N/A	N/A	N/A	-116.61%	-94.01%	11/5/2026 (Estimated)

Latest GRTS, INTS, ELOX, and DARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million
8/11/2026	Q2 2026	ELOX Eloxx Pharmaceuticals	N/A	-$0.66	N/A	-$0.66	N/A	N/A
8/11/2026	Q2 2026	INTS Intensity Therapeutics	-$0.8725	-$1.11	-$0.2375	-$1.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GRTS Gritstone bio	N/A	N/A	N/A	N/A	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DARE Dare Bioscience	N/A	0.99	0.99
ELOX Eloxx Pharmaceuticals	N/A	3.74	3.74
GRTS Gritstone bio	1.83	2.54	2.54
INTS Intensity Therapeutics	0.01	5.00	5.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DARE Dare Bioscience	6.70%
ELOX Eloxx Pharmaceuticals	2.90%
GRTS Gritstone bio	48.46%
INTS Intensity Therapeutics	3.74%

Insider Ownership

Company	Insider Ownership
DARE Dare Bioscience	4.10%
ELOX Eloxx Pharmaceuticals	25.90%
GRTS Gritstone bio	4.61%
INTS Intensity Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DARE Dare Bioscience	30	15.29 million	14.66 million	Not Optionable
ELOX Eloxx Pharmaceuticals	N/A	690,000	510,000	N/A
GRTS Gritstone bio	190	108.57 million	111.84 million	No Data
INTS Intensity Therapeutics	2,021	3.26 million	3.02 million	Not Optionable

GRTS, INTS, ELOX, and DARE Headlines

Recent News About These Companies

What is HC Wainwright's Forecast for INTS Q1 Earnings?

1 hour ago | americanbankingnews.com

Intensity Therapeutics (NASDAQ:INTS) Stock Price Expected to Rise, HC Wainwright Analyst Says

August 20 at 2:08 AM | americanbankingnews.com

Q3 EPS Estimates for INTS Cut by Brookline Capital Markets

August 20 at 1:28 AM | americanbankingnews.com

INTS FY2029 EPS Estimate Lifted by Brookline Capital Markets

August 17, 2026 | americanbankingnews.com

Analysts Set Intensity Therapeutics Inc. (NASDAQ:INTS) Target Price at $37.50

August 16, 2026 | americanbankingnews.com

Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3

August 11, 2026 | seekingalpha.com

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | prnewswire.com

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

August 4, 2026 | prnewswire.com

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

July 15, 2026 | prnewswire.com

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

July 1, 2026 | prnewswire.com

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why

May 27, 2026 | zacks.com

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

May 14, 2026 | prnewswire.com

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026 | prnewswire.com

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

May 1, 2026 | zacks.com

Intensity Therapeutics (INTS) price target decreased by 12.76% to 49.98

April 28, 2026 | msn.com

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know

April 16, 2026 | zacks.com

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

April 15, 2026 | prnewswire.com

Intensity Therapeutics (INTS) price target decreased by 11.32% to 57.29

April 9, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GRTS, INTS, ELOX, and DARE Company Descriptions

Dare Bioscience NASDAQ:DARE

$0.81 -0.02 (-1.84%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$0.80 -0.01 (-1.51%)

As of 08/20/2026 06:36 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Eloxx Pharmaceuticals NASDAQ:ELOX

$18.04 -0.12 (-0.66%)

As of 08/20/2026 04:00 PM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Gritstone bio NASDAQ:GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Intensity Therapeutics NASDAQ:INTS

$4.88 +0.68 (+16.19%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$4.64 -0.25 (-5.02%)

As of 08/20/2026 06:46 PM Eastern

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRTS, INTS, ELOX, and DARE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRTS, INTS, ELOX, and DARE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRTS, INTS, ELOX, and DARE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GRTS, INTS, ELOX, and DARE Company Descriptions

Dare Bioscience NASDAQ:DARE

Eloxx Pharmaceuticals NASDAQ:ELOX

Gritstone bio NASDAQ:GRTS

Intensity Therapeutics NASDAQ:INTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRTS, INTS, ELOX, and DARE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRTS, INTS, ELOX, and DARE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRTS, INTS, ELOX, and DARE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GRTS, INTS, ELOX, and DARE Company Descriptions

Dare Bioscience NASDAQ:DARE

Eloxx Pharmaceuticals NASDAQ:ELOX

Gritstone bio NASDAQ:GRTS

Intensity Therapeutics NASDAQ:INTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools